Press time:2021-07-21From:CR Pharma [ Font:BigMediumSmall]
On July 21, CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane), a subsidiary of China Resources Pharmaceutical Group Limited (Stock Code: 3320.HK), obtained exclusive authorization from U.S. company Novita Pharmaceuticals, Inc. for the development, production and commercialization, as well as the intellectual property right of NP-G2-044 Fascin inhibitor, a new target medicine, in Greater China (Mainland China, Hong Kong China, Macau China and Taiwan China).
Fascin inhibitor is a new molecular compound developed by NOVITA. According to previous research, NP-G2-044 can effectively curb the protein function of Fascin, thereby lowering tumor invasion and blocking tumor metastasis. This chemical compound is a prospective oral medicine for controlling tumor metastasis that could fill the void in tumor metastasis therapy. Based on past experience, there are certain risks in the development of new drugs. Therefore, CR Double-Crane will pay close attention to the progress of the project, and comply with its disclosure obligations in a timely manner in strict accordance with laws and regulations.
The signing of the agreement will further deepen the cooperation between the two parties in the research and development of small molecule drugs for anti-tumor therapy, and enrich the company’s R&D pipeline of small molecule anti-tumor drugs. The cooperation will also create favorable conditions for the R&D of new drugs in the future, thus promoting the development of the company.
